We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
BIO-RAD LABORATORIES

Download Mobile App





Group K Diagnostics Demonstrates KromaHealth Kit that Enables Lab-Quality Results at Point-of-Care

By LabMedica International staff writers
Posted on 29 Sep 2021
Print article
Image: KromaHealth Kit from Group K Diagnostics (Photo courtesy of Group K Diagnostics)
Image: KromaHealth Kit from Group K Diagnostics (Photo courtesy of Group K Diagnostics)

Group K Diagnostics (GKD; Philadelphia, PA, USA) demonstrated its KromaHealth Kit that enables point-of-care testing and fast results across a suite of various diagnostics at AACC 2021.

Every year, the global laboratory medicine community comes together at AACC to collaborate and create system-wide changes that improve patient outcomes and enhance the quality of life for all. The exhibition provides a platform to connect with the industry leaders making ground-breaking advancements in laboratory medicine, including clinical chemistry, molecular diagnostics, mass spectrometry, translational medicine, and lab management.

At this year’s AACC, GKD demonstrated its KromaHealth Kit which consists of a single-platform, versatile, point-of-care device, known as KromaHealth, paired with a mobile application used to read the test results, known as KromaViewer. Depending on the test, a user needs to simply place a few drops of blood, serum or urine on the device's testing sites to induce a color change that is translated into a clear diagnosis through an image processing algorithm. The process is simple and can be done in the physician's office with results provided before the patient leaves the physician’s office. The device is for investigational use only and its performance characteristics have not been established

GKD is currently developing the GKD Analytics Manager which is a dashboard for health system operators and researchers to monitor testing operations and collect anonymized results to analyze population health, disease management and compliance. GKD is also developing the MyGKD app which gives patients the ability view and track test results over time on their mobile phones. With this convenient access to their diagnostics, patients can own their results and be engaged in the effectiveness of their care.

Related Links:
Group K Diagnostics

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
Magnetic Bead Separation Modules
MAG and HEATMAG

Print article
AACC

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: Signs of multiple sclerosis show up in blood years before symptoms appear (Photo courtesy of vitstudio/Shutterstock)

Unique Autoantibody Signature to Help Diagnose Multiple Sclerosis Years before Symptom Onset

Autoimmune diseases such as multiple sclerosis (MS) are thought to occur partly due to unusual immune responses to common infections. Early MS symptoms, including dizziness, spasms, and fatigue, often... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: Microscope image showing human colorectal cancer tumor with Fusobacterium nucleatum stained in a red-purple color (Photo courtesy of Fred Hutch Cancer Center)

Mouth Bacteria Test Could Predict Colon Cancer Progression

Colon cancer, a relatively common but challenging disease to diagnose, requires confirmation through a colonoscopy or surgery. Recently, there has been a worrying increase in colon cancer rates among younger... Read more

Pathology

view channel
Image: A new study has identified patterns that predict ovarian cancer relapse (Photo courtesy of Cedars-Sinai)

Spatial Tissue Analysis Identifies Patterns Associated With Ovarian Cancer Relapse

High-grade serous ovarian carcinoma is the most lethal type of ovarian cancer, and it poses significant detection challenges. Typically, patients initially respond to surgery and chemotherapy, but the... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.